Meera Mehta, PharmD, says OPAT programs should move away from a “one-size-fits-all” monitoring model and instead tailor laboratory follow-ups based on patient risk factors, antimicrobial toxicity, and quality-of-life considerations.
Meera Mehta, PharmD
Advertisement
Mehta is an assistant professor, Clinical Pharmacy at West Virginia University.
Articles by Meera Mehta, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contagion Live
1
Lenacapavir and the Future of HIV Prevention: PURPOSE Trials, Long-Acting PrEP, and What Comes Next
2
Initiatives Look to Strengthen Vaccine Policy and Governance in US
3
Hackensack Meridian Health Joins Phase 3 Trial of Pfizer’s Investigational C difficile Vaccine
4
Considering Diversified Treatment Strategies to Combat Gonorrhea Resistance
5